Article ID Journal Published Year Pages File Type
8240214 International Journal of Radiation Oncology*Biology*Physics 2007 8 Pages PDF
Abstract
Subcutaneous amifostine was well tolerated by patients receiving chemoradiotherapy for SCCHN, with lower rates of nausea/vomiting than reported in trials with i.v. amifostine. Xerostomia and mucositis rates were similar to those reported in trials with i.v. amifostine.
Keywords
Related Topics
Physical Sciences and Engineering Physics and Astronomy Radiation
Preview
Efficacy and Safety of Subcutaneous Amifostine in Minimizing Radiation-Induced Toxicities in Patients Receiving Combined-Modality Treatment for Squamous Cell Carcinoma of the Head and Neck
Authors
, , , , , , , ,